Navigation Links
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Date:9/11/2007

a first-line randomized phase II/III study of the CHOP-R versus CPOP-R in previously untreated aggressive NHL patients. The study is evaluating replacing doxorubicin in the standard CHOP-R combination regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) with pixantrone as part of the CPOP-R regimen (cyclophosphamide, pixantrone, vincristine, prednisone and rituximab). The objective of the study is to demonstrate similar objective response rates to the standard doxorubicin-based therapy with significantly less severe cardiac toxicities and other doxorubicin-related toxicities on the CPOP-R arm of the study. A total of 280 patients are expected to be enrolled.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines. The main adverse events associated with pixantrone in clinical trials to date include myelosuppression and alopecia.

About NHL

According to the SEER CanQuest Database and the American Cancer Society, in 2005 the prevalence of indolent NHL in the U.S. was 282,025 with 24,490 newly diagnosed patients. The prevalence of aggressive NHL in the U.S. was 99,880 with 31,900 newly diagnosed patients.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology pro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015  St. Vincent Healthcare ... patient care. Already following strict disinfection routines, St. ... SmartUVC to eliminate harmful germs, like Ebola, methicillin-resistant ... norovirus that can infect patients during their hospital ... Logo - http://photos.prnewswire.com/prnh/20150420/199749LOGO ...
(Date:4/21/2015)... 2015 Legal cannabis markets, products ... at a rapid pace over the next five years ... services for indoor/outdoor cultivators and new cannabis products for ... (OTC: SRNA), Totally Hemp Crazy Inc. (OTC: THCZ), Medical ... 22 nd Century Group, Inc. (NYSE: XXII ...
(Date:4/21/2015)... -- IntelliQuit™, the world,s first smartphone breathalyzer for smokers, was selected to present as a finalist at ... on Wednesday April 22.  Photo ... ... ... Thirty percent (30%) of all cardiovascular disease is caused by smoking. The ...
Breaking Medicine Technology:St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 2St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 3New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 2New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 3New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 4New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 5New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 6New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 7IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 2IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 3
(Date:4/21/2015)... 2015 Patients seeking surgical treatment for ... choice for receiving treatment at a nationally accredited program ... quality of care in the greater Tampa area. ... center has been accredited as a Comprehensive Center under ... Program (MBSAQIP), a joint program of the American College ...
(Date:4/21/2015)... 21, 2015 Henry Mayo Newhall Hospital, ... Care Exchange to automatically send continuation of care ... to further improve communication with clinics and other ambulatory ... Alert solution. , “Provider Alert will enable ... patient information they need to provide continuing care in ...
(Date:4/21/2015)... “ ZeroWire ” was featured on ... takes a look at the latest and coolest technology ... special reporter for NewsWatch and a technology expert, conducted ... a security system and lifestyle management hub. , According ... 2 million burglaries in 2010. It goes without saying ...
(Date:4/21/2015)... BC (PRWEB) April 21, 2015 Angelo’s ... complimentary pick-up and delivery for clients that avail the ... Surrey by Angelo’s is done with hi-tech equipments, making ... for customers. They use all natural, high pressure steam ... well as hand washing for area rugs made with ...
(Date:4/21/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining how ... , SUVs are large vehicles that fare well in ... a smaller regular car shows that passengers from the first ... safer in crashes, but these large vehicles may be unstable ... It is now possible to find low cost car insurance ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Achieves National Accreditation from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program 2Health News:Florida Hospital Tampa Achieves National Accreditation from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program 3Health News:Florida Hospital Tampa Achieves National Accreditation from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program 4Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Auto Insurance Quotes For SUVs Are Available Online 2
... Treatment that increases brain levels of an important regulatory ... characterizes Huntington,s disease (HD) and other neurodegenerative disorders. ... Nature Medicine , a Massachusetts General Hospital (MGH)-based research ... a family of enzymes called sirtuins, in the brain ...
... The busy holiday season may disrupt many people,s daily routines, ... to remember to look after your teeth, an expert advises. ... treats and drink alcoholic beverages more than usual," Dr. George ... an academy news release. "Additionally, with their busy schedules ...
... Accelerated partial breast irradiation using brachytherapy (APBIb) for ... increasing over the last several years in the ... (WBI), according to a study published December 16th ... Cancer Institute . Various types of APBI ...
... , FRIDAY, Dec. 16 (HealthDay News) -- ,Draft recommendations ... trials for medical devices were released Friday by the ... size, diet, social and cultural factors, and types of ... medical products and devices than men, according to the ...
... scientists at the University of California, San Francisco has ... disorder called PKD/IC, or "paroxysmal kinesigenic dyskinesia with infantile ... disorders in older children. The study involved clinics ... London and Istanbul and may improve the ability of ...
... 16 (HealthDay News) -- Chronic pain can hinder communication ... partner,s ability to cope with the pain, according to ... validation of a spouse,s emotions (showing respect and acceptance) ... emotions (showing hostility or no interest) increases emotional distance ...
Cached Medicine News:Health News:Regulatory enzyme overexpression may protect against neurodegeneration in Huntington's disease 2Health News:Dentist Gives Advice to Keep Holiday Smiles Bright 2Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 2Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 3Health News:FDA Seeks to Get More Women Into Trials of Medical Devices 2Health News:UCSF-led team discovers cause of rare disease 2Health News:Spouse's Reaction May Affect Pain Management 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: